Spring brings renewal—and so does the health industry, as demonstrated at the 2026 Wuzhen Health Conference, held from April 12 to 16 at the Wuzhen Internet International Convention and Exhibition Center. Themed “Agility & Transformation: The Symphony of Tomorrow,” the event served as a pivotal gathering for China’s health ecosystem—bringing together policymakers, academic researchers, pharmaceutical innovators, and retail pharmacy leaders to advance strategic dialogue, cross-sector collaboration, and evidence-based commercialization of health solutions.
The conference hosted several flagship forums, including the 5th China OTC Summit, the Forum on New Quality Productivity in Traditional Chinese Medicine (TCM) and Pharmacy-Based Implementation, and the 5th TCM Anti-Aging Congress. These sessions spotlighted cutting-edge research, regulatory insights, and real-world integration strategies for TCM products within modern healthcare delivery channels.
Among the honorees was Shaanxi Panlong Pharmaceutical Group Co., Ltd., which received two prestigious “West Lake Awards” during the ceremony. Its flagship product, Panlong Qi Tablets—a proprietary TCM formula indicated for rheumatoid arthritis, osteoarthritis, and other chronic musculoskeletal conditions—was named “Most Popular Star Product in Pharmacies.” This marks the second consecutive year the formulation has earned this distinction, underscoring its consistent clinical acceptance, strong retail distribution network, and sustained patient adherence.
The West Lake Award for Star Products recognizes pharmaceuticals demonstrating exceptional market traction, robust channel integration, and long-term viability—criteria aligned with national priorities to strengthen domestic brand equity, elevate quality standards across the OTC and pharmacy-accessible TCM sectors, and accelerate the translation of traditional knowledge into scalable, patient-centered therapeutics.
In parallel, Mr. Ji-Lin Huang, Vice President of Panlong Pharmaceutical and General Manager of its Finished Pharmaceutical Marketing Center, was honored with the “West Lake Award for Outstanding Figure in China’s Pharmaceutical Industry.” The award acknowledges his leadership in advancing TCM commercialization frameworks, optimizing supply-chain integrity, and championing science-led positioning of herbal interventions within integrated care models.
Founded on the principle of “Building the Panlong Brand, Caring for Human Health,” the company adheres to the dual mandate of “Inheriting the Essence, Innovating with Integrity”—a philosophy reflected in its vertically integrated quality control system, from GACP-compliant herb cultivation through GMP-certified manufacturing and post-marketing pharmacovigilance. Its recognition at Wuzhen affirms not only the therapeutic credibility of its core products but also its institutional commitment to elevating TCM’s role in preventive, personalized, and population-level health strategies.
As China’s health industry navigates a period of structural transformation—marked by digital health integration, value-based reimbursement pilots, and intensified focus on aging-related disease burden—Panlong Pharmaceutical views the Wuzhen Health Conference as both a milestone and a catalyst. The company reaffirmed its dedication to accelerating R&D in clinically validated TCM formulations, deepening partnerships with community pharmacies and integrated health systems, and contributing substantively to national goals for high-quality, equitable, and innovation-driven health advancement.